期刊文献+

国产辛伐他汀片药代动力学及生物利用度研究 被引量:6

PHARMACOKINETICS AND RELATIVE BIOAVAILABILITY OF DOMESTIC SIMVASTATIN TABLET IN HEALTHY VOLUNTEERS
下载PDF
导出
摘要 12 名健康志愿者交叉口服单剂量国产辛伐他汀片和舒降之片剂 40 m g,应用 H P L C 法测定其经时血药浓度。实验数据经 3 P97 程序处理,两制剂口服吸收呈二室模型。辛伐他汀片和舒降之各相关药代动力学参数: Cm ax 为(105.97±25.98) μg/ L 和(110.32±27.67) μg/ L, Tm ax 为(1.90±037) h和(1.99±0.35) h, A U C 为(970.06±117.74)(μg/ L·h )和(976.81±150.13)(μg/ L·h ),根据辛伐他汀片和舒降之的代谢产物辛伐他汀酸( S V A)血药浓度时间曲线下面积 A U C,计算辛伐他汀片相对生物利用度为(98.62±12.01)% 。经方差分析及双单侧 T 检验和(1- 2α)置信区间分析,显示两制剂 A U C值在制剂间、周期间和个体间均无显著性差异,提示辛伐他汀片和舒降之片具有生物等效性。 A single oral dose of domestic simvastatin tablet or imported simvastatin tablet 40 mg was given to 12 healthy male volunteers in a randomized cross over clinical study. The serum concentrations of simvastatin acid were determined by HPLC.The pharmacokinetics parameters were analyzed by 3P97 software. It was found that the serum concentration time curve fitted to two compartment model, and the main pharmacokinetics parameters of domestic and imported tablets were as follows Cmax= (105.97±25.98) μg/L and (110.32±27.67)μg/L, Tmax=(1.90±0.37) h and (1.99±0.35) h, AUC=(970.06±117.74) μg/(L·h) and (976.81±150.13) μg/(L·h). The relative bioavailability of domestic was (98.62±12.01)%. These results suggested that there were no significant difference between the domestic and imported tablets. They are bioequivalent.
出处 《华西药学杂志》 CAS CSCD 北大核心 1999年第4期231-233,共3页 West China Journal of Pharmaceutical Sciences
关键词 辛伐他汀 高效液相色谱 生物利用度 药代动力学 Simvastatin HPLC Bioavailability Bioequivalent Pharmacokinetics
  • 相关文献

参考文献2

  • 1李家泰,临床药理学(第2版),1998年,158页
  • 2Albe A W,Proc Natl Acad Sci USA,1980年,77卷,3957页

同被引文献39

  • 1张红,徐文炜,胡晓,李艳艳,熊玉卿.人血浆中辛伐他汀的HPLC-MS/MS测定[J].中国医药工业杂志,2006,37(12):833-835. 被引量:15
  • 2[1]Todd PA,Goa KL.Simvastatin:a review of its pharmacological properties and therapeutic potential[J].Drugs,1990,40:583-607.
  • 3[4]Neuvonen PJ,Kantola T,Kivisto KT.Simvastatin but not pravas-rain is very susceptible to interaction with the CYP3A4 inhibitor itraconazole[J].Ciin Pharmacol Ther,1998,63:332-341.
  • 4Ross R. Atheroselerosis--an inflammatory disease [J]. N Engl J Med, 1999,340(2): 115-126.
  • 5Wang S, Bajorath J, Flies D B, et al, Molecular modeling and functional mapping B7-H1 and B7-DC uncouple costimulatory function from PD-1 interaction[J]. J Exp Med, 2003,197(9) : 1083-1091.
  • 6Yamazaki T, Akiba H, Koyanagi A, et al. Blockade of B7 HI on macrophages suppresses CD4 + T cell proliferation by augmenting IFN gamma induced nitric oxide production[J]. J Immunol, 2005,175 (3) : 1586-1592.
  • 7Latchman Y, Wood C R, Chemova T, et ah PD-L2 is a second ligand for PD-1 and inhibits T cell activation [J]. Nat Immunol, 2001,2 (3) : 261-267.
  • 8Levy Z, Rachmani R, Trestman S, et al. Low-dose interferon alphaaccelerates atherosclerosis in an LDL recep tot deficientmouse model[J]. Eur J Intern Med, 2003,14(8) 479 -483.
  • 9Kwak B, Mulhaupt F, Veillard N, et al. The HMG-CoA reductase inhibitor simvastatin inhibits IFN-gamma induced MHC class II expression in human vascular endothelial cells [J]. Swiss Med Wkly, 2001,131(3-4):41-46.
  • 10Jun Lee, Yan Zhuang, Xin Wei, et al. Contributions of PD- 1/PD-L1 pathway to interactions of myeloid DCs with T cells in atherosclerosis[J]. J Mol Cell Cardio, 2009,46(2) : 169- 176.

引证文献6

二级引证文献23

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部